Rabbit anti Human Sphingosine 1 Phosphate 4 Receptor (NT) (EDG6) NT

EDG6 (S1P4) belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG6 (S1P4) is sphingosine 1-phosphate. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C and several protein tyrosine kinases. EDG6 (S1P4) is expressed in lymphoid and hematopoietic tissue and in the lungs. _x000B_

Detects EDG6 (S1P4) receptors at concentration of 5-10 µg/mL by Western blot using a Human EDG6 (S1P4) receptor transfected cell line. Detects an approximately 45 kDa band in Cos cells transfected with full length Human EDG6 (S1P4) . Due to low expression of EDG receptors, we recommend use of Pierce Femto Signal substrate for western blot development.

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.

1. Yamazaki, Y., et al. 'EDG-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway.' Biochem. Biophys. Res. Commun. 2000, 268, 583-589._x000D_ 2. Van Brocklyn, J.R., et al. 'Sphingosine 1-phosphate is a ligand for the G protein-coupled receptor EDG-6.' Blood 2000, 95, 2624-2629._x000D_ 3. Takuwa, Y., et al. 'Subtype-specific, differential activities of the EDG family receptors for sphingosine 1-phosphate, a novel lysophospholipid mediator.' Mol. Cell Endocrinol. 2001, 177, 3-11._x000D_ 4. Ohotski, J., et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br. J. Can. (2012), 106, 1453-1459